Larimar Therapeutics
LRMR | NASDAQ
$3.00
-$0.02 (-0.66%)
At close: Nov 16, 2026, 4:00 PM ET
$3.03
+$0.03 (+1.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-0.66%
(1D)No price chart data available for 1D timeframe.
Rating
25.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #915/1021 (Top 90%)
Key Statistics
Market Data
Market Cap $311.65M
1D Range
2.89 3.29
52W Range
1.99 5.95
Valuation (TTM)
PE -1.51
PB 2.45
EV/EBITDA -0.93
Valuation (NTM)
Forward PE N/A
Forward PEG 0.05
Price Target $8.00
Cash Flow
FCF Yield -50.1%
SBC Adj. FCF Yield -52.5%
SBC Impact -4.8%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y -27.9% |
1.6%
FCF 3Y | 5Y -57.9% |
-43.1%
Returns
ROA -104.4%
ROE -137.4%
ROIC -135.3%
Financial Health
Net Cash
$156.27M
Current Ratio 4.70
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a dis...
Sector Healthcare
Industry Biotechnology
Employees 71
IPO Date Jun 19, 2014
Website www.larimartx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
3
Consensus
Buy
Price Target
$7.00
Upside
+133.33%
Buy (3)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove LRMR